IntelliPharmaCeutics International Company Profile (TSE:I)

About IntelliPharmaCeutics International (TSE:I)

IntelliPharmaCeutics International logoIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:I
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: C$3.41
  • 200 Day Moving Avg: C$3.41
  • 52 Week Range: C$1.78 - C$4.50
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Average Volume: 15,974 shs.

Frequently Asked Questions for IntelliPharmaCeutics International (TSE:I)

What is IntelliPharmaCeutics International's stock symbol?

IntelliPharmaCeutics International trades on the Tornton Stock Exchange (TSX) under the ticker symbol "I."

How were IntelliPharmaCeutics International's earnings last quarter?

IntelliPharmaCeutics International Inc. (TSE:I) issued its quarterly earnings data on Monday, April, 14th. The company reported $0.10 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.07. The firm earned $5.14 million during the quarter, compared to the consensus estimate of $3.63 million. View IntelliPharmaCeutics International's Earnings History.

Who are some of IntelliPharmaCeutics International's key competitors?

How do I buy IntelliPharmaCeutics International stock?

Shares of IntelliPharmaCeutics International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of IntelliPharmaCeutics International stock cost?

One share of IntelliPharmaCeutics International stock can currently be purchased for approximately C$3.23.

Analyst Ratings

Consensus Ratings for IntelliPharmaCeutics International (TSE:I) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for IntelliPharmaCeutics International (TSE:I)
No equities research coverage for this company has been tracked by


Earnings History for IntelliPharmaCeutics International (TSE:I)
Earnings by Quarter for IntelliPharmaCeutics International (TSE:I)
Earnings History by Quarter for IntelliPharmaCeutics International (TSE:I)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/14/2014$0.03$0.10$3.63 million$5.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IntelliPharmaCeutics International (TSE:I)
Current Year EPS Consensus Estimate: $0.23 EPS


Dividend History for IntelliPharmaCeutics International (TSE:I)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IntelliPharmaCeutics International (TSE:I)
Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)
Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/30/2015Penna Domenic DellaInsiderBuy3,510C$2.10C$7,371.00
11/25/2015Penna Domenic DellaInsiderBuy20,375C$1.87C$38,101.25
10/29/2015Bahadur MadhaniDirectorBuy1,000C$2.42C$2,420.00
(Data available from 1/1/2013 forward)


Headline Trends for IntelliPharmaCeutics International (TSE:I)
Latest Headlines for IntelliPharmaCeutics International (TSE:I)
DateHeadline logoIntellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - GlobeNewswire (press release) - May 24 at 5:41 PM logoIntellipharmaceutics Reports Director Election Results - GlobeNewswire (press release) - April 19 at 11:31 AM logoIntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected - April 13 at 10:23 AM logoBRIEF-Intellipharmaceutics announces patent litigation by Purdue against its Rexista abuse-deterrent extended-release Oxycodone - April 10 at 5:32 PM logoIntellipharmaceutics Announces TSX Trading Symbol Change to “IPCI” - March 16 at 4:27 PM logoBRIEF-Intellipharmaceutics announces FDA approval for 500 mg and 750 mg generic Glucophage XR - February 25 at 12:06 AM logoIntellipharmaceutics Announces 2016 Year End Results - February 10 at 6:32 PM logoQ4 2016 IntelliPharmaCeutics International Inc Earnings Release - 4:00 pm ET - February 7 at 7:05 PM logoIntellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain - February 2 at 6:30 PM logoIntellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical - Yahoo Finance - January 8 at 5:44 AM logoIntellipharmaceutics to Present at the Biotech Showcase™ - GlobeNewswire (press release) - December 29 at 5:52 PM logoIntellipharmaceutics awarded patents covering PODRAS technology - Seeking Alpha - December 23 at 4:05 AM



IntelliPharmaCeutics International (I) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff